Neos Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference

DALLAS and FORT WORTH, Texas, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. NEOS, a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and manufacture central nervous system (CNS)-focused products, today announced that Jerry McLaughlin, chief executive officer, will present a company overview at the upcoming Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 2, 2019 at 9:30 a.m. ET in New York, NY.

A live webcast of the presentation will be available on the Investor Relations page of the Company's website at http://investors.neostx.com/. Following the presentation, a replay of the webcast will be available on Neos' website for 30 days. 

About Neos Therapeutics

Neos Therapeutics, Inc. NEOS is a commercial-stage pharmaceutical company utilizing its novel microparticle delivery technology to develop and manufacture central nervous system (CNS)-focused products. The Company has three approved produced, all for the treatment of ADHD, that utilize the Company's extended-release technology platform: Adzenys XR-ODT^® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT^® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys-ER^® (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING). Additional information about Neos is available at www.neostx.com.

CONTACTS:

Richard I. Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com

Sarah McCabe
Investor Relations
Stern Investor Relations, Inc.
(212) 362-1200
sarah.mccabe@sternir.com